Introduction
============

The CD4+ T-lymphocyte count is the method recommended by the World Health Organization (WHO) to assess eligibility for antiretroviral treatment (ART).[@R1]^,^[@R2] The CD4+ count also guides the clinical management of people living with human immunodeficiency virus (HIV).[@R2] WHO recommends testing of viral load to detect treatment failure, but the CD4+ count continues to be used for ART monitoring if viral load cannot be tested.[@R3] In settings where viral load can be determined, WHO suggests that routine CD4+ monitoring may be reduced or stopped for adults who are virologically stable.[@R4]^,^[@R5]

Increased availability of ART has driven the establishment of laboratories analysing CD4+ count, but access to CD4+ testing requires adequate laboratory capacity and the means to transport specimens.[@R6]^,^[@R7] Point-of-care CD4+ testing provides rapid results without the need to transport specimens and is considered an important tool to improve patient retention in care before treatment initiation.[@R8]^--^[@R11]

The Alere Pima CD4+ analyser (Alere Technologies, Jena, Germany) was commercially launched in 2010. It is an automated analyser intended for counting CD4+ cells in capillary or venous whole blood within 20 minutes. The analyser is portable; can be operated with a rechargeable battery; contains dried thermostable reagents and can be stored at room temperature. The analyser performs a series of checks to ensure that all steps of the analysis are completed successfully, if not, an invalid result is reported. It is recommended that internal Pima Bead cartridges are analysed daily for quality control purposes. The analyser fulfils most WHO criteria for point-of-care tests[@R12] and is on the WHO list of prequalified diagnostics.[@R13]

The analyser has been extensively evaluated with favourable diagnostic performance at laboratory level[@R14]^--^[@R25] and with acceptable results at clinic level,[@R26]^--^[@R40] in mobile clinics[@R41] and in communities.[@R42]^,^[@R43] Some studies showed higher variability of results at clinic level with capillary sampling.[@R44]^--^[@R46] A recent meta-analysis showed that the analyser was comparable in performance to laboratory-based methods. The analyser identifies patients for treatment at the 350 CD4+ cells/μL threshold with a sensitivity of 91.6% and specificity of 94.8%.[@R47]

In 2011, Médecins Sans Frontières (MSF) introduced the analyser in various projects to make CD4+ counting more accessible and to reduce loss to follow-up. During the implementation phase, several MSF sites reported a relatively high proportion of errors. Previous studies have reported invalid results ranging from 2% to 15%.[@R29]^,^[@R32]^,^[@R38]^,^[@R39] However, these studies have been conducted under validation conditions and there is a lack of data describing errors under routine field conditions. Given the relatively high proportion of invalid results reported at MSF sites, we carried out a retrospective analysis of analyser data across a variety of settings. The objective of the study was to describe the proportion of CD4+ test errors and identify factors associated with these errors. We hypothesized that invalid results might be related to the experience of the operators or to the type of blood sample used.

Methods
=======

Study population
----------------

We conducted a retrospective, observational, cross-sectional study using routine data from 39 MSF-supported sites using the analyser in the Central African Republic, the Democratic Republic of the Congo, Guinea, India, Kenya, Lesotho, Malawi, Mozambique and South Africa, between 1 January 2011 and 30 June 2013. Analysers were introduced in laboratories, primary health-care clinics, mobile clinics and in communities. HIV-positive individuals requiring ART eligibility assessment, and in some instances, ART monitoring, had CD4+ counts done on capillary or venous blood samples. The study protocol was submitted to the MSF ethics review board and exempted from ethics review because it complied with the standards for routinely collected data analyses.

Training
--------

Laboratory technicians, clinicians and lay workers, were trained either by MSF-trained personnel or by the local Alere representative before use of the analyser. On-site training was conducted in half a day and focused on device operation, sampling technique, quality control and data management. In Lesotho and South Africa, a three-day centralized course in Alere's training department in Cape Town was also provided to key staff who, in turn, trained multiple users on-site.

Sampling technique
------------------

Venous blood samples were used at all sites in the Central African Republic, the Democratic Republic of the Congo, Guinea, India, Kenya, Malawi and two sites in South Africa; capillary sampling was used in Lesotho, Mozambique and the remaining nine sites in South Africa. All sites in the Central African Republic, the Democratic Republic of the Congo, Guinea, India, Kenya and Malawi used a fixed volume micropipette to transfer 25 µL of venous blood to the cartridge. Two sites in South Africa used a plain capillary tube for cartridge filling. Capillary sampling was performed using the Alere recommended safety lancet (Sarstedt, Nümbrecht, Germany) at remaining sites in South Africa and all sites in Mozambique and Lesotho.

Quality control
---------------

Daily quality control was done at all sites using the manufacturer-supplied bead standards (with normal and low CD4+ cell counts) before testing patient samples. Eleven sites in South Africa were also enrolled in a regional proficiency testing programme and tested stabilized whole blood samples with normal or low CD4+ counts every two months.[@R48] At most sites, dedicated paper-based registers were implemented to capture test results. None of the sites made use of the Alere online data portal during the study period. Test results and quality control data were analysed periodically in each country by a laboratory coordinator.

Data collection
---------------

Archived computer files containing CD4+ test results and quality control data were collated from each device. Information about the setting, user, training, sampling technique and device repair history were obtained by questionnaire, completed by the laboratory coordinator in each country. To ensure a representative number of tests per device and to eliminate errors due to inexperienced operators, we excluded data from devices with less than 50 tests, users performing less than 50 tests or unknown operators.

Analysis
--------

We calculated the proportion of invalid CD4+ test results by device and by operator. Factors associated with invalid results were analysed using the binreg command in Stata version 13.0 (StataCorp. LP, College Station, United States of America). To determine the effects of user type and setting, we performed a series of analyses, restricted to those countries with comparable user type and setting.

We carried out the following comparisons: (i) tests done at clinics by lay workers versus tests done by clinicians in South Africa; (ii) tests done by laboratory technicians at clinics versus tests done at laboratories in the Central African Republic and the Democratic Republic of the Congo, and (iii) tests done by lay health workers in mobile settings versus tests done in clinics in Lesotho, Mozambique and South Africa. For each of these three comparisons, we calculated the frequency of errors stratified by country and tested for effect modification by country using the Mantel-Haenszel *χ^2^* test. If there was no effect modification by country, we used generalized linear regression models to assess associations between error frequency and user type or setting. The *χ*^2^ test for categorical variables and the two-sample test of proportions were used to assess the significance of differences; a *P*-value of less than 0.05 was considered statistically significant.

Results
=======

Between January 2011 and June 2013, there were 27 019 records in the data set. The exclusion criteria led to 1403 tests being removed, leaving 25 616 records from nine countries, across 39 sites, for 58 devices and 180 end-users. The characteristics of the participating sites are shown in [Table 1](#T1){ref-type="table"}. Most tests were done in fixed clinics (13 892; 54.2%), followed by home-based testing (5913; 23.1%), mobile clinics (3924; 15.3%) and laboratories (1887; 7.4%). Tests were done by laboratory staff (8230; 32.0%), clinicians (8188; 32.0%) and lay workers (9198; 36.0%). Most tests were done on venous blood (15 596; 61.0%) and the remainder on capillary blood (10 020; 39.0%). The median number of users per device was 3 (interquartile range, IQR: 2--5); the median number of tests per device was 470 (IQR: 252--672) and the median number of tests per user was 106 (IQR: 50--216).

###### Characteristics of participating sites, nine countries, 2011--2013

  Country                            Sample type         User type                          Settings                                       Users, No.   Devices, No.   Tests, No.   Invalid tests, No. (%)
  ---------------------------------- ------------------- ---------------------------------- ---------------------------------------------- ------------ -------------- ------------ ------------------------
  Central African Republic           Venous blood        Laboratory technician              1 clinic, 1 laboratory                         10           3              1925         362 (18.8)
  Democratic Republic of the Congo   Venous blood        Laboratory technician, clinician   2 laboratories, 2 clinics, 1 mobile clinic     25           5              1888         254 (13.4)
  Guinea                             Venous blood        Laboratory technician              2 clinics                                      10           2              1896         150 (7.9)
  India                              Venous blood        Laboratory technician              2 clinics                                      5            2              1235         60 (4.9)
  Kenya                              Venous blood        Laboratory technician, clinician   2 clinics, 2 laboratories, mobile clinics^a^   26           11             5717         670 (11.7)
  Lesotho                            Capillary blood     Clinician, lay worker              6 clinics, 3 mobile clinics                    40           10             4434         681 (15.4)
  Malawi                             Venous blood        Clinician                          Mobile clinics^a^                              10           7              1520         358 (23.6)
  Mozambique                         Capillary blood     Lay worker                         Mobile clinics                                 6            2              1554         136 (8.8)
  South Africa                       Venous, capillary   Clinician, lay worker              8 clinics, 3 mobile clinics                    49           16             5447         683 (12.5)
  **Total**                          --                  --                                 **39**                                         **180**      **58**         **25 616**   **3354 (13.1)**

^a^ Home-based testing.

Invalid results
---------------

There were 3354 invalid results: (13.1%) overall; with 4.9% for India, 7.9% for Guinea, 8.8% for Mozambique, 11.7% for Kenya, 13.4% for the Democratic Republic of the Congo, 12.5% for South Africa, 15.4% for Lesotho, 18.8% for the Central African Republic and 23.6% for Malawi. There were 12.7% errors per device (IQR: 10.3--19.9) and 12.1% per user (IQR: 7.1--19.2).

Source of errors
----------------

The most common errors were code 850 (37.0%) and code 880 (18.0%). These errors can result from multiple causes ([Fig. 1](#F1){ref-type="fig"}). Based on the error codes, the source of the error was the user (1542; 46.0%); user or device (1519; 45.3%); device (83; 2.5%); or sample (147; 4.4%); with the remaining 63 errors (1.9%) being of unknown origin ([Fig. 2](#F2){ref-type="fig"}). For calibration tests using Pima beads, 2% generated errors (207/10 404), with error codes 203 and 840 being the most common.
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Associated factors
------------------

The factors associated with invalid tests are shown in [Table 2](#T2){ref-type="table"}. Compared to South Africa, invalid tests were lowest in India (risk ratio; RR: 0.36; 95% confidence interval, CI: 0.27--0.46) and highest in Malawi (RR: 1.72; 95% CI: 1.50--1.97). Compared to tests done in 2013, there were fewer invalid tests in 2011 and 2012, but there was no significant secular trend. Users were significantly more likely to experience invalid results within their first 50 tests, but once they had done 50 tests or more, there was no trend towards a lower frequency of invalid results as their level of experience increased further. The frequency of errors was not correlated with the number of users per device.

###### Factors associated with errors using the Alere Pima CD4+ analyser for CD4+ T-lymphocyte counts, nine countries, 2011--2013

  Characteristic                       RR (95% CI)
  ------------------------------------ -------------------
  **Country**                          
  South Africa                         (reference)
  Central African Republic             1.47 (12.9--1.66)
  Democratic Republic of the Congo     1.04 (0.90--1.20)
  Guinea                               0.60 (0.50--0.71)
  India                                0.36 (0.27--0.46)
  Kenya                                1.02 (0.92--1.13)
  Lesotho                              1.19 (1.07--1.32)
  Malawi                               1.72 (1.50--1.97)
  Mozambique                           0.65 (0.54--0.78)
  **Time period**                      
  2013                                 (reference)
  2011                                 0.88 (0.77--1.02)
  2012                                 0.81 (0.74--0.89)
  **Cumulative operator experience**   
  1--49 tests                          (reference)
  50--99 tests                         0.86 (0.78--0.94)
  100--199 tests                       0.88 (0.81--0.97)
  ≥ 200 tests                          0.90 (0.83--0.99)
  **Operators per device**             
  1 operator                           (reference)
  2--3 operators                       1.06 (0.97--1.17)
  4--5 operators                       1.09 (0.98--1.20)
  ≥ 6 operators                        0.93 (0.83--1.03)
  **Sample Type**^a^                   
  Venous blood                         (reference)
  Capillary blood                      0.46 (0.40--0.53)

CI: confidence interval; RR: risk ratio.

^a^ Sub-analysis restricted to South Africa.

In clinics in South Africa, errors were significantly less frequent for lay health workers than clinicians (9.9% versus 19.8%; *P* = 0.001). Among laboratory technicians, the association between setting and the frequency of invalid tests differed by country. In the Central African Republic, invalid tests among laboratory technicians were more frequent at the clinic than at the laboratory (22.4% versus 16.3%; *P* \< 0.001), while in the Democratic Republic of the Congo, invalid tests among laboratory technicians were less frequent at the clinic than at the laboratory (13.2% versus 18.7%; *P* \< 0.001). Among lay health workers in Lesotho, Mozambique and South Africa, the association between setting and the frequency of invalid tests differed by country: in South Africa and Lesotho, the frequency of invalid tests was comparable in mobile clinic and fixed clinic settings (9.0% versus 9.9% in South Africa; *P* = 0.35; and 15.5% versus 16.1% in Lesotho; *P* = 0.66). However, in Mozambique, the frequency of invalid tests in mobile clinics was considerably lower than in fixed clinics (4.1% versus 13.6%; *P* \< 0.001).

Blood sample type
-----------------

There were fewer invalid results when capillary blood samples were used (12.0%, versus 14.0% for venous blood samples; *P* \< 0.001). In a subgroup multivariate analysis restricted to South Africa, (the only country in which both sample types were used) this association was strengthened (RR: 0.46; 95% CI: 0.40--0.53).

Discussion
==========

Under routine field conditions, the proportion of invalid CD4+ test results ranged from 5% in India to 24% in Malawi. Previous studies have reported comparable ratios from 5% in Thailand to 19% in South Africa.[@R15]^,^[@R33] In our study, invalid results were slightly more frequent in venous blood samples than capillary blood samples. The use of a pipette to fill the device cartridge may generate air bubbles; since the CD4+ test is based on image detection, the presence of air bubbles may affect the results. To decrease the generation of air bubbles, the manufacturer recommends that capillary tubes instead of pipettes be used to transfer venous blood to the device. Studies in Senegal and Uganda reported more errors using capillary blood specimens (14% and 18%) compared to venous blood specimens (5% and 8%).[@R31]^,^[@R44] However, other studies using venous blood have also found high ratios of invalid results: 10% in Ethiopia, 11% in USA and 15% in South Africa.[@R16]^,^[@R18]^,^[@R45] Some studies have shown an increased variability of Alere Pima CD4+ results when capillary blood is used.[@R20]^,^[@R44]^,^[@R45] However, a recent systematic review and meta-analysis found that capillary blood yielded more accurate results than venous blood.[@R47] The fact that errors were more likely to occur using venous blood in our study may be related to the pipetting skills of laboratory staff. Therefore, training of laboratory staff in pipetting skills is as important as training clinic staff to perform capillary bleeds required for field testing.

The proportion of invalid samples for calibration tests was low (2%); however, in some instances, operators did not know how to interpret the results, so that testing continued despite clear indication of a problem; this calls for retraining. Multiple factors probably contribute to the wide variability of invalid results among countries, sites, devices and operators in our study. We did not find a clear association between the number of operators per device, the type of operator or the setting. Prospective studies under field conditions, specifically designed to evaluate the effect of various factors on the invalid tests are needed.

There were several limitations resulting from the retrospective nature of our study. We could not analyse errors according to cartridge lot number because this information was not contained in the cartridge barcode and sites did not document lot numbers systematically. It proved impossible to identify lot numbers via orders, as they were placed through various procurement centres in Europe as well as purchased from local distributors. We were unable to link results of repeat testing due to errors, so it was not possible to estimate the proportion of valid or invalid results after a second test. During the study period, none of the sites made use of online data systems for the analyser. Remote analysers can be connected to a centralised data warehouse via the internet, which could improve the timeliness of monitoring.

The high proportion of invalid CD4+ test results, necessitating the use of a second cartridge, raises the cost of testing per patient.[@R49] Overall, 3354 tests had to be repeated; at a current price of 6 United States dollars (US\$) per test, this translates to a cost of US\$ 20 124. Repeat tests take time to process, decrease throughput, and oblige the patient to provide another blood sample if capillary sampling is used.

Training, monitoring, quality assessment and troubleshooting are essential aspects of point-of-care testing.[@R50] It is important that post-market surveillance is done regularly and manufacturers continue to make the necessary improvements to their technologies and to supply service, maintenance and training for the full lifespan of the device.

In conclusion, 13.1% of results from the Alere Pima CD4+ analyser were invalid in this study. Most errors could be attributed to the operator but elucidating the exact cause proved to be difficult. Analyser errors are frequent and need to be factored into the implementation and operational cost for routine CD4+ testing.
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